Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05863052 · ClinicalTrials.gov registry record
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
A clinical trial of Melanoma and Renal Cell Carcinoma, sponsored by University of Oklahoma.
- Active
- Registry status
- 72
- Enrollment target
- 6
- Study locations
NCT05863052 is a study of Melanoma and Renal Cell Carcinoma that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 72 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT05863052, a study of Melanoma and Renal Cell Carcinoma, is active but no longer recruiting, sponsored by University of Oklahoma.
- ACTIVE NOT RECRUITING
- Registry status
- 72 participants
- Enrollment target
- 6
- Study locations
Study Summary
The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Conditions Studied
Interventions
- BIOLOGICAL Immunotherapy
Study Locations (6)
South Dakota
- Monument Health Cancer Care Institute - Rapid City
- Avera Cancer Institute - Sioux Falls
Arizona
- Arizona Cancer Center at the Unvieristy of Arizona - Tucson
New Mexico
- University of New Mexico Comprehensive Cancer Center - Albuquerque
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05863052
The ClinicalTrials.gov registry entry for NCT05863052 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (90% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Immunotherapy is the first listed.
NCT05863052 reports 6 study locations spanning 5 distinct geographic areas - top geographies include South Dakota, Arizona, New Mexico.
Frequently Asked Questions
What is clinical trial NCT05863052 about?
NCT05863052 is a clinical study titled "Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population". The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventiona...
What is the current status of trial NCT05863052?
This trial is currently active not recruiting. The enrollment target is 72 participants. The study started on 2022-01-31. Estimated completion is 2027-12.
What conditions does trial NCT05863052 study?
This clinical trial studies the following conditions: Melanoma, Renal Cell Carcinoma, Metastatic Solid Tumor, Gastrointestinal Cancer, Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05863052?
The interventions under investigation include: Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT05863052?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05863052 being conducted?
This trial has 6 study locations across Arizona, New Mexico, Oklahoma, South Dakota, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.